Search results for "Coagulation"

showing 10 items of 381 documents

Self-assembled multivalent (SAMul) ligand systems with enhanced stability in the presence of human serum

2019

Self-assembled cationic micelles are an attractive platform for binding biologically-relevant polyanions such as heparin. This has potential applications in coagulation control, where a synthetic heparin rescue agent could be a useful replacement for protamine, which is in current clinical use. However, micelles can have low stability in human serum and unacceptable toxicity profiles. This paper reports the optimi- sation of self-assembled multivalent (SAMul) arrays of amphiphilic ligands to bind heparin in competitive conditions. Specifically, modification of the hydrophobic unit kinetically stabilises the self-assembled nanostructures, preventing loss of binding ability in the presence of…

02 engineering and technologyheparinLigands01 natural sciencesMicelleGeneral Materials ScienceMicellesnanomaterialsMolecular StructurenanotechnologybiologyChemistrybiomaterialself-assemblyHeparinsimulation021001 nanoscience & nanotechnologyCholesterolhydrolysisThermodynamics0210 nano-technologyHydrophobic and Hydrophilic Interactionsbiomaterialsmedicine.drugBiocompatibilityCell Survivalmicellesexperimental characterizationserum albuminBiomedical EngineeringSerum albuminself-assembly; nanotechnology; biomaterials; simulation; experimental characterization010402 general chemistrySurface-Active Agentsthermodynamicsbiocompatibilitytoxicity testingAmphiphilemedicineHumansMTT assaycoagulationhydrophobicityHeparinLigandligandscholesteroltoxicitybinding capacityProtaminemolecular dynamicsNanostructures0104 chemical sciencesKineticsblood serumbiology.proteinBiophysicshuman cell linesanions
researchProduct

Recombinant factor VIII: past, present and future of treatment of hemophilia A.

2018

The development of recombinant factor VIII (rFVIII) was initially driven by the necessity to treat hemophilia A (HA) patients with FVIII concentrates without the risk of transmitting infectious agents. Over the last three decades the safety of rFVIII has been further improved by completely removing animal or human proteins from the manufacturing process, so that patients would not be exposed to known or emerging pathogens. Recent efforts have concentrated on improving the expression of rFVIII, reducing its immunogenicity and enhancing its pharmacokinetic (PK) behavior. These new goals have been possible thanks to the develop-ment of biotechnology and a better knowledge of the function and s…

0301 basic medicine030204 cardiovascular system & hematologyPharmacologyStandard half-life FVIIIHemophilia ARecombinant factor viiiHemostaticslaw.inventionCoagulation factor disorder03 medical and health sciences0302 clinical medicineHemostaticlawExtended half-life FVIIIMedicineHumansPharmacology (medical)Mode of actionPharmacologyFactor VIIIbiologybusiness.industryManufacturing processImmunogenicityHuman cellRecombinant ProteinRecombinant FVIIIRecombinant Proteins030104 developmental biologyTreatment OutcomeConsumer Product Safetybiology.proteinRecombinant DNAPEGylationAntibodybusinessDrug ContaminationHumanHalf-LifeDrugs of today (Barcelona, Spain : 1998)
researchProduct

Analysis of cold activation of the contact system in hereditary angioedema with normal C1 inhibitor.

2021

Hereditary angioedema (HAE) attacks are caused by excessive activation of the contact system. Understanding how the contact system is activated in HAE, especially in patients with normal C1 inhibitor (HAEnCI), is essential to effectively treat this disease. Contact system activation involves the cleavage of several proteins including Factor XII (FXII), high molecular weight kininogen (HK), prekallikrein, sgp120 (ITIH4) and C1 inhibitor (C1-INH) before the subsequent generation of bradykinin that mediates HAE. In this study, we evaluated the fragmentation and enzymatic activity of contact system proteins in HAEnCI plasma samples before and after contact system activation induced by incubatio…

0301 basic medicineAdultMalemedicine.medical_specialtyHigh-molecular-weight kininogenImmunologyProteinase Inhibitory Proteins SecretoryBradykininBradykininC1-inhibitorHereditary Angioedema Type III03 medical and health scienceschemistry.chemical_compoundYoung Adult0302 clinical medicineInternal medicinemedicineHumansFragmentation (cell biology)Molecular BiologyBlood CoagulationFactor XIIbiologyKininogensPrekallikreinPrekallikreinEstrogensPlasminogenKallikreinMiddle Agedmedicine.diseaseCold Temperature030104 developmental biologyEndocrinologychemistryHereditary angioedemaFactor XIIbiology.proteinFemaleKallikreinsComplement C1 Inhibitor Protein030215 immunologyMolecular immunology
researchProduct

Proteases, Protease-Activated Receptors, and Atherosclerosis

2018

Coagulation activation by the TF (tissue factor) pathway plays pivotal roles in triggering platelets and precipitating acute coronary syndromes. Although dual antiplatelet therapy is effective in secondary cardiovascular prevention, combining platelet antagonism with low-dose aspirin and the oral coagulation FXa antagonist rivaroxaban has a synergistic clinical benefit over monotherapy in preventing the composite outcome of cardiovascular death, stroke, or myocardial infarction.1 It is, therefore, of considerable interest to understand the roles of coagulation proteases and their cell signaling effects in the development of atherosclerosis and vascular inflammation. Acute thrombosis in anim…

0301 basic medicineApolipoprotein EProteasesReceptors Proteinase-Activated030204 cardiovascular system & hematologyArticleMice03 medical and health sciencesTissue factor0302 clinical medicineThrombinEndopeptidasesAnimalsReceptor PAR-2MedicinePlateletbusiness.industryArteriosclerosisAtherosclerosismedicine.diseaseThrombosis030104 developmental biologyCoagulationCancer researchCardiology and Cardiovascular MedicinebusinessPeptide Hydrolasesmedicine.drugArteriosclerosis, Thrombosis, and Vascular Biology
researchProduct

CD36-fibrin interaction propagates FXI-dependent thrombin generation of human platelets.

2019

Thrombin converts fibrinogen to fibrin and activates blood and vascular cells in thrombo-inflammatory diseases. Platelets are amplifiers of thrombin formation when activated by leukocyte- and vascular cell-derived thrombin. CD36 on platelets acts as sensitizer for molecules with damage-associated molecular patterns, thereby increasing platelet reactivity. Here, we investigated the role of CD36 in thrombin-generation on human platelets, including selected patients with advanced chronic kidney disease (CKD). Platelets deficient in CD36 or blocked by anti-CD36 antibody FA6.152 showed impaired thrombin generation triggered by thrombin in calibrated automated thrombography. Using platelets with …

0301 basic medicineBlood PlateletsCD36 AntigensCD36InflammationFibrinogenBiochemistryFibrin03 medical and health sciences0302 clinical medicineThrombinBlocking antibodyGeneticsmedicineHumansPlateletRenal Insufficiency ChronicMolecular BiologyFactor XIFibrinbiologyChemistryCell adhesion moleculeThrombinPlatelet ActivationBlood Coagulation FactorsCell biology030104 developmental biologybiology.proteinmedicine.symptom030217 neurology & neurosurgerycirculatory and respiratory physiologyBiotechnologymedicine.drugFASEB journal : official publication of the Federation of American Societies for Experimental BiologyREFERENCES
researchProduct

Comment on “Endothelial Protein C Receptor (EPCR), Protease Activated Receptor-1 (PAR-1) and Their Interplay in Cancer Growth and Metastatic Dissemin…

2019

Although the interplay between tumor progression and blood coagulation has been recognized [...]

0301 basic medicineCancer ResearchEndothelial protein C receptorChemistryCancermedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenslcsh:RC254-28203 medical and health sciences030104 developmental biology0302 clinical medicineProtease-Activated Receptor 1n/aOncologyCoagulationTumor progression030220 oncology & carcinogenesisCancer researchmedicineCancers
researchProduct

Bacitracin and Rutin Regulate Tissue Factor Production in Inflammatory Monocytes and Acute Myeloid Leukemia Blasts

2021

Simple Summary Aberrant tissue factor (TF) expression by transformed myeloblasts and inflammatory monocytes contributes to coagulation activation in acute myeloid leukemia (AML). TF procoagulant activity (PCA) is regulated by protein disulfide isomerase (PDI), an oxidoreductase with chaperone activity, but its specific role in AML-associated TF biology is unclear. Here, we provide novel mechanistic insights into this interrelation. We show that bacitracin and rutin, two pan-inhibitors of the PDI family, prevent lipopolysaccharide (LPS)-induced monocyte TF production under inflammatory conditions and constitutive TF expression by THP1 cells and AML blasts, thus exerting promising anticoagula…

0301 basic medicineCancer ResearchMyeloidDaunorubicinacute myeloid leukemia030204 cardiovascular system & hematologyPeripheral blood mononuclear cellArticleFlow cytometry03 medical and health sciencesTissue factor0302 clinical medicineDownregulation and upregulationhemic and lymphatic diseasesmedicinecoagulationProtein disulfide-isomeraseRC254-282medicine.diagnostic_testChemistryrutinNeoplasms. Tumors. Oncology. Including cancer and carcinogensMyeloid leukemiatissue factorprotein disulfide isomeraseMolecular biology030104 developmental biologymedicine.anatomical_structureOncologyinflammationtissue factor; protein disulfide isomerase; acute myeloid leukemia; coagulation; inflammation; rutin; monocytesmonocytesmedicine.drugCancers
researchProduct

Cumulative visual impact of two coagulability disorders: A case report.

2020

Cumulative visual impact of two coagulability disorders were reviewed by presenting a case of a young female patient with a spontaneous abortion and two thromboembolic events in 8 years, whose visual function was severely affected. The particularities of her genetic constellation regarding the retinal circulation are also discussed. The patient developed a central retinal artery occlusion in the right eye during pregnancy in 2010, which led to an extended hematological workup that revealed presence of MTHFR C677T and MTHFR A1298C heterozygote mutations. The screening for myeloproliferative disorders showed JAK2 V617F gene mutation. Test results confirmed the diagnosis of thrombophilia and e…

0301 basic medicineCancer Researchmedicine.medical_specialtyVisual acuitygenetic structuresRetinal ArteryGene mutationThrombophilia03 medical and health sciences0302 clinical medicineImmunology and Microbiology (miscellaneous)Central retinal vein occlusionInternal medicinemedicinepapillophlebitiscoagulationVeincentral retinal artery occlusionthrombophiliaessential thrombocythemiabusiness.industrycentral retinal vein occlusionGeneral MedicineArticlesmedicine.diseaseThrombosiseye diseases030104 developmental biologymedicine.anatomical_structure030220 oncology & carcinogenesisCardiologyCentral retinal artery occlusionmedicine.symptombusinessExperimental and therapeutic medicine
researchProduct

Tissue factor at the crossroad of coagulation and cell signaling

2018

The tissue factor (TF) pathway plays a central role in hemostasis and thrombo-inflammatory diseases. Although structure-function relationships of the TF initiation complex are elucidated, new facets of the dynamic regulation of TF?s activities on cells continue to emerge. Cellular pathways that render TF non-coagulant participate in signaling of distinct TF complexes with associated proteases through the protease-activated receptor (PAR) family of G-protein coupled receptors. Additional coreceptors, including the endothelial protein C receptor (EPCR) and integrins, confer signaling specificity by directing subcellular localization and trafficking. We here review how TF is switchedbetween it…

0301 basic medicineCell signalingProteasesCIENCIAS MÉDICAS Y DE LA SALUDIntegrinInmunologíaFactor VIIaThromboplastin03 medical and health sciencesTissue factorPROTEINASE- ACTIVATED RECEPTORSNeoplasmsmedicineAnimalsHumansReceptor PAR-2Myeloid CellsHEMOSTASISProtease-activated receptorENDOTHELIAL PROTEIN C RECEPTORBlood CoagulationInflammationEndothelial protein C receptorInnate immune systembiologyChemistryEndothelial CellsThrombosisInflammasomeHematologyCell biologyTHROMBOSISMedicina Básica030104 developmental biologyFactor Xabiology.proteinPROTEIN DISULFIDE-ISOMERASESSignal Transductionmedicine.drugJournal of Thrombosis and Haemostasis
researchProduct

Distinct contributions of complement factors to platelet activation and fibrin formation in venous thrombus development

2017

Expanding evidence indicates multiple interactions between the hemostatic system and innate immunity, and the coagulation and complement cascades. Here we show in a tissue factor (TF)-dependent model of flow restriction-induced venous thrombosis that complement factors make distinct contributions to platelet activation and fibrin deposition. Complement factor 3 (C3) deficiency causes prolonged bleeding, reduced thrombus incidence, thrombus size, fibrin and platelet deposition in the ligated inferior vena cava, and diminished platelet activation in vitro. Initial fibrin deposition at the vessel wall over 6 hours in this model was dependent on protein disulfide isomerase (PDI) and TF expressi…

0301 basic medicineComplement component 5biologyChemistryImmunologyCell BiologyHematologyComplement factor I030204 cardiovascular system & hematologymedicine.diseaseBiochemistryFibrinCell biologyComplement system03 medical and health sciences030104 developmental biology0302 clinical medicineCoagulationImmunologymedicinebiology.proteinPlateletPlatelet activationThrombusBlood
researchProduct